Stocks to sell

ContextLogic (NASDAQ:WISH) is set to announce its third-quarter earnings today under a new CFO. But there probably won’t be a lot to celebrate when the report is released. Ultimately, that means investing in WISH stock isn’t going to be worthwhile. Source: sdx15 / Shutterstock.com That said, ContextLogic will remain a popular choice for risk-tolerant retail

There are plenty of opportunities as the market heads higher. But despite the positive direction, there are still plenty of stocks to sell. First, let’s take a look at some of the positives. Unemployment numbers are going down and vaccinations are going up. The pandemic is losing its teeth, the global supply chain issues are

InvestorPlace columnist Larry Ramer recently argued that Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) and Qualcomm (NASDAQ:QCOM) would become potential buyers of BlackBerry (NYSE:BB) once they become more familiar with the company’s QNX operating system. Ramer believes that’s a good reason to buy BB stock.     Source: Shutterstock “[C]ompanies can’t hire enough cybersecurity experts to protect themselves from ruinous hacks,

Facing potentially huge competition and generating gigantic losses, Affirm (NASDAQ:AFRM) stock has a poor outlook at this point. Source: Piotr Swat / Shutterstock.com Affirm has developed a Buy Now Pay Later (BNPL) offering. BNPL allows consumers to buy items now and pay for them in fixed installments. Sometimes Affirm’s BNPL factors in interest payments, while

Lucid Group (NASDAQ:LCID) stock has been on a tear. It’s up 59% in the past month and 317% year to date. Source: Around the World Photos / Shutterstock.com Much of that short-term run is because the company actually rolled 20 cars out of its factory and delivered them. I guess that this is where we are

Ocugen (NASDAQ:OCGN) stock didn’t move much on a recent announcement that it had applied to the FDA for a new emergency use authorization (EUA) for the Covaxin coronavirus vaccine. Source: shutterstock.com/PhotobyTawat This EUA is for people between the ages of two and 18, but the move is extremely unlikely to prevent OCGN stock from sliding in

Palantir Technologies (NYSE:PLTR) hasn’t fully recovered since pulling back with the overall market in late September. But PLTR stock has still managed to slowly move higher in recent weeks. Source: Ascannio / Shutterstock.com To some extent, this uptrend makes sense. After all, the “story” behind this stock remains intact. The company has continued to post strong

Virgin Galactic (NYSE:SPCE) has been on a bad downward spiral. From a recent peak of $55.91 on June 25, SPCE stock is now near a low point of $19.55. However, despite this, don’t act on the urge just yet to bargain hunt in this stock. Source: rafapress / Shutterstock.com I forewarned investors that this could

Ocugen (NASDAQ:OCGN) is a stock that I continue to be wrong about. Over the past month, OCGN stock has gained more than 80%, greatly testing my patience. The stock has fallen from the $17 mark it reached this morning, but is still higher than I expected last month. Source: shutterstock.com/PhotobyTawat In my last article about

If you’ve read my prior articles on Ocugen (NASDAQ:OCGN), you know full well my heavily bearish view about OCGN stock. What’s the story here? The company is trying to bring Covaxin, a Covid-19 vaccine candidate developed by India’s Bharat Biotech, to the U.S. and Canada. Source: shutterstock.com/PhotobyTawat So far, it’s made little progress obtaining Emergency

Microvision (NASDAQ:MVIS) specializes in providing a technology known as lidar, or light detection and ranging. There’s currently only a handful of ways to invest directly in the lidar market, and MVIS stock is one of them. Source: temp-64GTX/Shutterstock.com Just to give you a quick primer, lidar systems use laser beams to form a three-dimensional image of

Over the trailing year, a majority of my single-company opinions have been at least middle of the road for obvious reasons. Although I do have broader economic concerns, benchmark indices have proven resilient. So, my headline to consider exiting Novavax (NASDAQ:NVAX) stock might seem controversial. Source: Ascannio/Shutterstock.com However, I genuinely believe taking the green ink

Covid-19 vaccine giant Moderna (NASDAQ:MRNA) has been on a tear since the second quarter of 2020.  It has grown its top line by over 6,500% on a year-over-year basis due to rampant sales of its Covid-19 vaccine. As a consequence, it now trades at a whopping valuation hardly justified by its long-term outlook. The lack of

The only question left regarding Uber Technologies (NYSE:UBER) stock is: where’s the bottom? Source: NYCStock / Shutterstock.com At around $45.70 per share, the ride-hailing and food delivery company’s stock is well down from its 52-week high of $64.05. UBER stock has fallen 14% in the past six months, and the share price is now up

Peloton Interactive (NASDAQ:PTON) was a pandemic favorite. With gyms shut down and people stuck at home, they snapped up Peloton’s pricey internet-connected exercise bikes and treadmills. But in the spring, with gyms reopening and the outdoors beckoning, sales quickly dropped off. Then things got even worse for PTON stock. Source: JHVEPhoto / Shutterstock.com It put

Lucid Group (NASDAQ:LCID) stock is getting a Tesla (NASDAQ:TSLA) valuation before it demonstrates Tesla performance. Source: gg5795 / Shutterstock.com LCID stock has jumped 50% in just a few weeks as the company began deliveries of its Air sedan. The cars are getting reviews a lot like the early Tesla cars, filled with superlatives. But Lucid

When it comes to Vinco Ventures (NASDAQ:BBIG) stock, investors continue to dig a larger hole for themselves rather than crafting a successful “mining operation” in the shares. Source: shutterstock.com/Postmodern Studio Let me explain. But first, let’s take a little trip back on memory lane to better understand how BBIG stock landed where it is today.

The reason for investing in Ocugen (NASDAQ:OCGN) stock hasn’t changed. Bulls expect the FDA to allow Ocugen to market Bharat Biotech’s Covaxin vaccine in the U.S., enabling Ocugen to generate massive sales and rapidly boost OCGN stock.   Source: shutterstock.com/PhotobyTawat The problems with this thesis, though, remain the same as they’ve ever been. Despite a great

SmileDirectClub (NASDAQ:SDC) is an oral care company founded in 2014. Headquartered in Nashville, the company operates in the North America, Europe and Asia Pacific regions. Its primary offering is a clear aligner therapy treatment, but it also sells a variety of oral care products, such as whitening kits and gels, toothbrushes, toothpastes and water flossers. SDC

On Oct. 27, Ocugen (NASDAQ:OCGN) confirmed the truth of a point I’ve been making for many months: the FDA will require the company to conduct a U.S.-based trial of Covaxin before the agency will even consider approving it. Specifically, on Oct. 27, Ocugen announced that it had submitted an application to the FDA to conduct